Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02685293 · ClinicalTrials.gov registry record · Phase 3
Study to Evaluate the Treatment Effect of PT003 on Cardiovascular Hemodynamics in Subjects With Moderate to Severe COPD
A Phase 3 study, sponsored by Pearl Therapeutics.
- Terminated
- Registry status
- Phase 3
- Development phase
- 4
- Enrollment target
NCT02685293 is a Phase 3 study that was terminated before completion, run by Pearl Therapeutics. The registered enrollment target is 4 participants.
The verdict
NCT02685293, a Phase 3 study, was terminated before completion, sponsored by Pearl Therapeutics.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 4 participants
- Enrollment target
Study Summary
This is a randomized, double-blind, placebo-controlled, single-center, chronic-dosing (7 days), two-period, two-treatment, cross-over study to evaluate the treatment effect of PT003 compared with that of Placebo MDI on Cardiovascular Hemodynamics following chronic-dosing (7 days) in subjects with moderate to severe COPD.
Interventions
- DRUG Placebo MDI
- DRUG GFF MDI (PT003)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2016-12-09 |
| Est. Completion | 2018-06-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02685293
The ClinicalTrials.gov registry entry for NCT02685293 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pearl Therapeutics, which has 31 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo MDI is the first listed.
NCT02685293 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02685293 about?
NCT02685293 is a clinical study titled "Study to Evaluate the Treatment Effect of PT003 on Cardiovascular Hemodynamics in Subjects With Moderate to Severe COPD". This is a randomized, double-blind, placebo-controlled, single-center, chronic-dosing (7 days), two-period, two-treatment, cross-over study to evaluate the treatment effect of PT003 compared with that of Placebo MDI on Cardiovascular Hemodynamics following chronic-dosing (7 days) in subjects with mo...
What is the current status of trial NCT02685293?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 4 participants. The study started on 2016-12-09. Estimated completion is 2018-06-06.
What interventions are being tested in trial NCT02685293?
The interventions under investigation include: Placebo MDI (DRUG), GFF MDI (PT003) (DRUG).
Who is sponsoring clinical trial NCT02685293?
This trial is sponsored by Pearl Therapeutics, which has 31 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.